Publicacións nas que colabora con Juan J. Gómez Doblas (34)

2023

  1. Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

    Journal of Clinical Medicine, Vol. 12, Núm. 12

  2. Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  3. Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study

    Clinical Cardiology, Vol. 46, Núm. 11, pp. 1390-1397

  4. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

    Revista Española de Cardiología (English Edition), Vol. 75, Núm. 5, pp. 364-369

  2. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing

    Journal of Clinical Medicine, Vol. 11, Núm. 20

  3. Spanish citizens’ opinions on future trends in cardiology as expressed in digital ecosystems

    Humanities and Social Sciences Communications, Vol. 9, Núm. 1

  4. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 1, pp. 4-11

2021

  1. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19

    Age and ageing, Vol. 50, Núm. 2, pp. 326-334

  2. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  3. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

    Internal and Emergency Medicine, Vol. 16, Núm. 4, pp. 957-966

  4. Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. A Delphi consensus on the management of oral anticoagulation in patients with nonvalvular atrial fibrillation in Spain: ACOPREFERENCE study

    PLoS ONE, Vol. 15, Núm. 6

  2. Baseline ECG and Prognosis After Transcatheter Aortic Valve Implantation: The Role of Interatrial Block

    Journal of the American Heart Association, Vol. 9, Núm. 22, pp. e017624

  3. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  4. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

2019

  1. Abordaje integral del paciente con diabetes mellitus tipo 2 y enfermedad cardiovascular o de muy alto riesgo cardiovascular

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 183-192

  2. Comprehensive approach to the patient with diabetes mellitus and cardiovascular disease or very high cardiovascular risk

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 183-192

  3. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

    Thrombosis Journal, Vol. 17, Núm. 1

  4. Prognosis of Patients With Severe Aortic Stenosis After the Decision to Perform an Intervention

    Revista Espanola de Cardiologia, Vol. 72, Núm. 5, pp. 392-397